SANTA CLARA, Calif., Oct. 18 -- Lumenis Ltd. announced this week that two of its products have received marketing clearance from the US Food & Drug Administration (FDA); its Novus Varia multicolor photocoagulation laser system was approved for the treatment of a variety of retinal diseases, and its Selecta Duet combination laser system was cleared for treating open angle and angle closure glaucoma as well as secondary cataracts.
After the announcement of FDA for clearance of the photocoagulation laser system, shares of the Yokneam, Israel-based company closed Tuesday at $4.37, up 69 cents, or nearly 19 percent, on Nasdaq. Lumenis reported sales of $315.2 million last year.
Lumenis said the photocoagulation laser system is the first diode laser to offer the spectrum of green, yellow and red light in one standard platform. The FDA approved the laser to treat eye problems such as age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinopathy of prematurity and retinal vein occlusions.
The Selecta Duet integrates the Lumenis patented selective laser trabeculoplasty platform with advanced photodisruptor Nd:YAG laser technology.
For more information, visit: www.lumenis.com